Drug Profile

MT 218

Alternative Names: MT-218; ZD2-N3-Gd(HP-DO3A)

Latest Information Update: 23 Sep 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Molecular Theranostics
Class Diagnostic conjugates; Gadolinium-containing contrast agents; Peptide diagnostics
Mechanism of Action Magnetic resonance imaging enhancers

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase I/II Prostate cancer
Phase I Solid tumours

Most Recent Events

23 Sep 2025 MT 218 is still in phase I clinical trials in Solid tumours (Diagnosis, In volunteers) in USA (IV)
25 Jul 2024 Phase-I/II clinical trials in Prostate cancer (Diagnosis) in USA (IV) (NCT06262139)
15 Feb 2024 Molecular Theranostics plans a phase I/II trial for Prostate cancer (Diagnosis) in USA (IV) in March 2024 (NCT06262139)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com